Cogeco Communications Inc. (CCA) EPS Estimated At $1.52; Biodelivery Sciences International (BDSI)’s Sentiment Is 1

December 8, 2017 - By Hazel Jackson

BioDelivery Sciences International, Inc., a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products principally in the areas of pain management and addiction. The company has market cap of $153.68 million. The firm provides its products based on its patented BioErodible MucoAdhesive drug delivery technology, which consists of a small, erodible polymer film for application to the buccal mucosa. It has a 27.23 P/E ratio. It offers ONSOLIS, a fentanyl buccal soluble film to treat breakthrough pain in opioid patients with cancer; BUNAVAIL, a buprenorphine and naloxone buccal film for the treatment of opioid dependence; and BELBUCA, a buprenorphine buccal film for the treatment of chronic pain.

Analysts expect Cogeco Communications Inc. (TSE:CCA) to report $1.52 EPS on January, 10.They anticipate $0.00 EPS change or 0.00% from last quarter’s $1.52 EPS. T_CCA’s profit would be $74.90 million giving it 14.83 P/E if the $1.52 EPS is correct. After having $1.48 EPS previously, Cogeco Communications Inc.’s analysts see 2.70% EPS growth. The stock increased 3.11% or $2.72 during the last trading session, reaching $90.16. About 177,590 shares traded or 80.18% up from the average. Cogeco Communications Inc. (TSE:CCA) has 0.00% since December 8, 2016 and is . It has underperformed by 16.70% the S&P500.

Cogeco Communications Inc. operates as a communications corporation in North America. The company has market cap of $4.44 billion. The firm operates in three divisions: Canadian Broadband Services, American Broadband Services and Business Information and Communications Technology Services. It has a 14.95 P/E ratio. It offers video services and programming, such as basic services, pay and discretionary services, On-demand services, high definition television, and advanced video services; Internet services; and telephony services to residential customers.

Among 7 analysts covering Cogeco Cable Inc. (TSE:CCA), 3 have Buy rating, 1 Sell and 3 Hold. Therefore 43% are positive. Cogeco Cable Inc. had 25 analyst reports since October 9, 2015 according to SRatingsIntel. RBC Capital Markets maintained it with “Outperform” rating and $78 target in Wednesday, January 13 report. The firm has “Market Perform” rating given on Friday, July 8 by BMO Capital Markets. The stock of Cogeco Communications Inc. (TSE:CCA) has “Buy” rating given on Tuesday, January 19 by TD Securities. The rating was maintained by Scotia Capital with “Outperform” on Friday, November 4. On Tuesday, April 11 the stock rating was downgraded by Barclays Capital to “Underweight”. The stock has “Buy” rating by Desjardins Securities on Tuesday, January 12. The firm has “Outperform” rating given on Friday, April 7 by Scotia Capital. Desjardins Securities maintained it with “Buy” rating and $72 target in Friday, July 8 report. The company was upgraded on Monday, October 26 by Canaccord Genuity.

Broadfin Capital Llc holds 1.74% of its portfolio in BioDelivery Sciences International, Inc. for 5.12 million shares. Grandeur Peak Global Advisors Llc owns 1.14 million shares or 0.46% of their US portfolio. Moreover, Hikari Power Ltd has 0.23% invested in the company for 601,285 shares. The California-based Eam Investors Llc has invested 0.22% in the stock. Sterling Investment Management Inc., a Arizona-based fund reported 50,000 shares.

Analysts await BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to report earnings on March, 16. They expect $-0.22 EPS, up 24.14% or $0.07 from last year’s $-0.29 per share. After $-0.21 actual EPS reported by BioDelivery Sciences International, Inc. for the previous quarter, Wall Street now forecasts 4.76% negative EPS growth.